Which venture capital firms get the best returns? In our latest 50-page STAT Report, Kate Sheridan answers just this with a definitively ranked list of more than a dozen of the biggest names in biotech investment: including Third Rock Ventures, OrbiMed, ARCH Venture Partners, and even Flagship Pioneering.
Join STAT’s leading DC bureau as they take the stage with policymakers, patient advocates, and industry experts to discuss the biggest issues in health policy…
House lawmakers are aiming to pass the BIOSECURE ACT in time for it to be included in a year-end must-pass legislative package.
MultiPlan faces a class action lawsuit alleging the company and insurers “conspired to fix, suppress, and stabilize” medical payments.
Rebuilding trust in the CDC won’t be quick or easy — especially in a divisive political season — but that doesn’t make it any less…
As national awareness of mental illness rises and innovative care models emerge, many advocates now see a rare opportunity to remake mental health crisis care…
A new Science paper from the Baker lab details a novel method for quickly compiling a large library of macrocycle drug candidates.
Cigna plans to make copies of AbbVie’s Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
Boston, Mass. STAT, the leading health and science news publication, and the Knight Science Journalism Program at the Massachusetts Institute of
STAT’s Casey Ross and Bob Herman have won the Batten Medal, one of the most prestigious awards in American journalism, for their “Denied by AI”…
Improving prior authorization requires shifting to a more collaborative framework focused on the medical evidence and what’s best for each patient.
